Category: <span>Research Findings</span>
In June 2023 Bellberry were delighted to host the “Towards a Coordinated Approach for Managing Accelerated Patient Access to Potentially Beneficial Medicines: Balancing Patient, Regulator, Health Technology Assessment (HTA), Payer, and Other Stakeholder Needs” international workshop in Adelaide.
This event brought together over a global delegation from over 20 nations including the US, UK, Europe, Canada, Singapore, and Japan from a range of stakeholder groups to discuss the issue of a gap in funded access to potentially beneficial medicines where there has been accelerated regulatory approval. All aspects of the workshop programme were overseen by a Scientific Committee and were chaired by E/Prof Lloyd Sansom.
The workshop was followed by a one-day open day meeting where the deliberations and conclusions of the expert panel presented and debated amongst a wider local audience. The workshop outcome was the development of an agreed statement of good practice, guidelines on approaches and a clear agreement on required next steps.
The full report from the workshop can now be viewed here, key themes from the report were integrated into a meeting statement that can be viewed here.
In June 2023 Bellberry were delighted to host the “Towards a Coordinated Approach for Managing Accelerated Patient Access to Potentially Beneficial Medicines: Balancing Patient, Regulator, Health Technology Assessment (HTA), Payer, and Other Stakeholder Needs” international workshop in Adelaide.
This event brought together over a global delegation from over 20 nations including the US, UK, Europe, Canada, Singapore, and Japan from a range of stakeholder groups to discuss the issue of a gap in funded access to potentially beneficial medicines where there has been accelerated regulatory approval. All aspects of the workshop programme were overseen by a Scientific Committee and were chaired by E/Prof Lloyd Sansom.
The workshop was followed by a one-day open day meeting where the deliberations and conclusions of the expert panel presented and debated amongst a wider local audience. The workshop outcome was the development of an agreed statement of good practice, guidelines on approaches and a clear agreement on required next steps.
The full report from the workshop can now be viewed here, key themes from the report were integrated into a meeting statement that can be viewed here.
Report of an international workshop convened by Bellberry, held on November 18-20, in Sydney, Australia
In November 2019 Bellberry were delighted to host the “Challenges of Valuing and paying for Combination Therapies in Oncology” international workshop in Sydney.
This event brought together over 50 experts from around the world from a range of stakeholder groups to discuss the challenges associated with valuing and paying for combination regimens in oncology. All aspects of the workshop programme were overseen by a Scientific Committee and were chaired by E/Prof Lloyd Sansom.
The workshop was followed by a one-day open day meeting where the deliberations and conclusions of the expert panel presented and debated amongst a wider local audience. The workshop outcome was the development of an agreed statement of good practice, guidelines on approaches and a clear agreement on any required next steps.
The full workshop report can be viewed here
In October 2014 Bellberry hosted the Crossover conference, an international expert scientific meeting that addressed the challenges of early treatment switching in clinical trial design for oncology. A further scientific meeting in 2015 allowed for the development and launch of best practice guidelines for trial design and statistical methods from an international expert panel.
Bellberry are pleased to announce the publication of two papers arising from the scientific meetings, which have now been accepted by the International Journal of Technology Assessment in Health Care (Cambridge University Press.)
The first is entitled ‘Treatment Switching: Statistical and Decision Making Challenges and Approaches’ (N. Latimer, C.Henshall, U. Siebert and H. Bell)
The second is entitled ‘Treatment Switching in Cancer Trials: Issues and Proposals’ (N. Latimer, C. Henshall, L.Sansom and R. Ward)
James Cook University researchers search to see if bitter and ugly cucumber may be cancer cure
Bellberry HREC has featured in an article in the Cairns Post regarding the supported research they have provided to James Cook University researchers.